NBP
NBP
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $7.114M ▲ | $-5.504M ▼ | 0% | $-0.069 ▲ | $-7.114M ▼ |
| Q1-2025 | $0 | $5.266M ▼ | $-3.15M ▲ | 0% | $-0.28 ▼ | $-5.266M ▲ |
| Q4-2024 | $0 | $13.371M ▲ | $-9.062M ▲ | 0% | $-0.11 ▲ | $-12.098M ▼ |
| Q3-2024 | $0 | $12.412M ▼ | $-20.491M ▼ | 0% | $-0.25 ▼ | $-6.422M ▲ |
| Q2-2024 | $0 | $258.954M | $25.126M | 0% | $0.3 | $-103.081M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $165.614M ▼ | $206.708M ▼ | $9.975M ▼ | $196.733M ▼ |
| Q1-2025 | $168.622M ▼ | $208.941M ▼ | $10.6M ▼ | $198.341M ▼ |
| Q4-2024 | $173.398M ▼ | $212.68M ▼ | $11.52M ▼ | $201.16M ▼ |
| Q3-2024 | $184.391M ▼ | $232.682M ▼ | $14.799M ▼ | $217.883M ▼ |
| Q2-2024 | $1.508B | $253.827M | $17.194M | $236.633M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-13.268M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q1-2025 | $-22.869M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q4-2024 | $-66.144M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q3-2024 | $-143.798M ▼ | $0 | $0 | $0 | $0 | $0 |
| Q2-2024 | $180.072M | $0 | $0 | $0 | $0 | $0 |
Revenue by Products
| Product | Q3-2020 | Q4-2020 | Q2-2022 | Q4-2022 |
|---|---|---|---|---|
 Grant | $10.00M ▲ | $0 ▼ | $0 ▲ | $20.00M ▲ |
 Licensing and Collaboration | $0 ▲ | $0 ▲ | $20.00M ▲ | $0 ▼ |
 Supply Of Investigational Products | $0 ▲ | $0 ▲ | $30.00M ▲ | $0 ▼ |
NEWS
November 20, 2025 · 8:00 PM UTC
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Read more
October 29, 2025 · 6:27 PM UTC
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Read more
October 29, 2025 · 9:00 AM UTC
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
Read more
October 28, 2025 · 10:00 AM UTC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Read more
October 23, 2025 · 10:00 AM UTC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Read more
About NovaBridge Biosciences
https://www.i-mabbiopharma.comNovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $7.114M ▲ | $-5.504M ▼ | 0% | $-0.069 ▲ | $-7.114M ▼ |
| Q1-2025 | $0 | $5.266M ▼ | $-3.15M ▲ | 0% | $-0.28 ▼ | $-5.266M ▲ |
| Q4-2024 | $0 | $13.371M ▲ | $-9.062M ▲ | 0% | $-0.11 ▲ | $-12.098M ▼ |
| Q3-2024 | $0 | $12.412M ▼ | $-20.491M ▼ | 0% | $-0.25 ▼ | $-6.422M ▲ |
| Q2-2024 | $0 | $258.954M | $25.126M | 0% | $0.3 | $-103.081M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $165.614M ▼ | $206.708M ▼ | $9.975M ▼ | $196.733M ▼ |
| Q1-2025 | $168.622M ▼ | $208.941M ▼ | $10.6M ▼ | $198.341M ▼ |
| Q4-2024 | $173.398M ▼ | $212.68M ▼ | $11.52M ▼ | $201.16M ▼ |
| Q3-2024 | $184.391M ▼ | $232.682M ▼ | $14.799M ▼ | $217.883M ▼ |
| Q2-2024 | $1.508B | $253.827M | $17.194M | $236.633M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-13.268M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q1-2025 | $-22.869M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q4-2024 | $-66.144M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q3-2024 | $-143.798M ▼ | $0 | $0 | $0 | $0 | $0 |
| Q2-2024 | $180.072M | $0 | $0 | $0 | $0 | $0 |
Revenue by Products
| Product | Q3-2020 | Q4-2020 | Q2-2022 | Q4-2022 |
|---|---|---|---|---|
| Grant | $10.00M ▲ | $0 ▼ | $0 ▲ | $20.00M ▲ |
| Licensing and Collaboration | $0 ▲ | $0 ▲ | $20.00M ▲ | $0 ▼ |
| Supply Of Investigational Products | $0 ▲ | $0 ▲ | $30.00M ▲ | $0 ▼ |
NEWS
November 20, 2025 · 8:00 PM UTC
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Read more
October 29, 2025 · 6:27 PM UTC
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Read more
October 29, 2025 · 9:00 AM UTC
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
Read more
October 28, 2025 · 10:00 AM UTC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Read more
October 23, 2025 · 10:00 AM UTC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Read more
CEO
Xi-Yong Fu
Compensation Summary
(Year 2024)
CEO
Xi-Yong Fu